menu
    • menu

    Company profile for Leukogene Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Leukogene Therapeutics is an oncology focused biotech company based in Charleston, South Carolina, and a spin out from the Medical University of South Carolina. We are dedicated to developing innovative immunotherapies for hard to treat cancers, with a focus on immunologically cold tumors. Our MHC class II targeted M2T immunotherapy activates a strong tumor antigen specific immune response to eliminate cancer cells. Lead progr...
    Leukogene Therapeutics is an oncology focused biotech company based in Charleston, South Carolina, and a spin out from the Medical University of South Carolina. We are dedicated to developing innovative immunotherapies for hard to treat cancers, with a focus on immunologically cold tumors. Our MHC class II targeted M2T immunotherapy activates a strong tumor antigen specific immune response to eliminate cancer cells. Lead programs in AML and PDAC have shown preclinical proof of concept. Leukogene is part of the NCI and SCRA SC Launch portfolio.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Leukogene TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Blue Sky Labs, QE308C-D 280 Calhoun St. Charleston, SC 29425
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://leukogene.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Leukogene Announces Two Presentations at the AACR Annual Meeting
    Leukogene Announces Two Presentations at the AACR Annual Meeting

    13 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-13/leukogene-therapeutics-announces-two-presentations-at-the-aacr-annual-meeting-2026-highlighting-mhc

    PHARMIWEB
    13 Apr 2026
    Share Share
    Leukogene Secures SCRA Funding for Cancer Immunotherapy
    Leukogene Secures SCRA Funding for Cancer Immunotherapy

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112798827/en/Leukogene-Therapeutics-Receives-Strategic-Funding-from-South-Carolina-Research-Authority-to-Accelerate-Development-of-Its-Cancer-Immunotherapy-Pipeline

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    FDA Designates Leukogene's M2T-CD33 For Acute Myeloid Leukemia
    FDA Designates Leukogene's M2T-CD33 For Acute Myeloid Leukemia

    05 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251105454890/en/U.S.-FDA-Grants-Orphan-Drug-Designation-to-Leukogene-Therapeutics-M2T-CD33-LTI-214-for-the-Treatment-of-Acute-Myeloid-Leukemia

    BUSINESSWIRE
    05 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search